Sensei Biotherapeutics (SNSE) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

SNSE · Stock Price

USD 23.76-7.80 (-24.71%)

Market Cap: $32.1M

Historical price data

Market Cap: $32.1MFounded: 2015HQ: Boston, United States

Sector Ranking#60 in Immunotherapy / Immuno-Oncology #137 in Oncology (General)

Overview

Sensei Biotherapeutics is a Boston-based, clinical-stage biotech focused on next-generation cancer therapeutics. Following a transformative 2024 acquisition, the company's strategy now centers on PIKTOR, a multi-node PI3K/AKT/mTOR inhibitor combined with dietary intervention, representing a novel metabolic modulation approach. The company is also advancing solnerstotug, a VISTA-targeting immunotherapy, through Phase 1/2 trials. With a compact pipeline and a distressed public market valuation, Sensei represents a high-risk, high-potential turnaround story in the competitive oncology landscape.

Oncology

Technology Platform

A bifurcated platform featuring a legacy immuno-oncology TMAb™ technology for conditional antibody activation in the tumor microenvironment, and a newly central metabolic modulation platform combining multi-node PI3K/AKT/mTOR pathway inhibition with prescribed dietary intervention.

Funding History

3

Total raised:$211M

IPO$126MUndisclosedJan 28, 2021

Series B$50MTaiho VenturesJan 15, 2020

Series A$35MMPM CapitalJun 15, 2018

Opportunities

PIKTOR addresses a large market in PI3K-altered cancers with a novel 'drug + diet' approach that could differentiate it from toxic single-agent inhibitors.

Success could position Sensei as a leader in metabolic modulation for oncology, attracting partnership or acquisition interest.

Risk Factors

Extreme financial distress with a ~$30M valuation limits runway and necessitates dilutive financing.

The unproven clinical efficacy of the core 'drug + diet' paradigm and the high-risk VISTA target create significant binary biological risk.

The company is a micro-cap competing in crowded fields against much larger players.

Competitive Landscape

PIKTOR faces intense competition from numerous approved and clinical-stage PI3K/AKT/mTOR inhibitors from large pharma and biotech. Solnerstotug competes in the unvalidated VISTA checkpoint space, which has seen prior clinical failures. Sensei's primary differentiation is the novelty of its combined metabolic therapy approach.